<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02082457</url>
  </required_header>
  <id_info>
    <org_study_id>YKP10811_IBS_II_2013</org_study_id>
    <nct_id>NCT02082457</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation</brief_title>
  <acronym>YKP</acronym>
  <official_title>Multi-center, Randomized, Double Blinded, Placebo-controlled, Phase II Trial to Assess the Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is to investigate efficacy and safety of YKP10811 in Subjects With Irritable Bowel
      Syndrome With Constipation. The difference of responder rate between test group (10, 20 and
      40mg) and placebo will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abdominal pain intensity &amp; stool frequency responder</measure>
    <time_frame>12weeks</time_frame>
    <description>an improvement of equl and more than 30% from baseline in the average of the daily worst abdominal pain score and an increase of equal and more than 1 CSBM from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>subject global assessment</measure>
    <time_frame>12 weeks</time_frame>
    <description>the degree of symptom relief on abdominal pain, bloating, stool frequency, stool consistency, etc.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">273</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two tablets of YKP10811 placebo are administered orally once a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YKP10811 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two tablets of YKP10811 5mg are administered orally once a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YKP10811 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet of YKP10811 20mg and one tablet of placebo are administered orally once a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YKP10811 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two tablets of YKP10811 20mg are administered orally once a day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YKP10811 5mg</intervention_name>
    <arm_group_label>YKP10811 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YKP10811 20mg</intervention_name>
    <arm_group_label>YKP10811 20mg</arm_group_label>
    <arm_group_label>YKP10811 40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YKP10811 placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>YKP10811 20mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. more than 18 years old

          2. patients met with ROME III criteria for C-type IBS

        Exclusion Criteria:

          -  pregnancy or lactation

          -  a history of surgery for gastrointestinal tract

          -  a history of gastrointestinal bleeding, diverticulitis and ileus within 1 year of
             screening visit

          -  inflammatory bowel disease or malignant tumor within 5 years of screening visit

          -  taking drugs that could have impact on efficacy assessment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo jin Park, MD.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gang Nam Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gang Nam Severance Hospital</name>
      <address>
        <city>Gang Nam Gu</city>
        <state>Seoul</state>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>March 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2014</study_first_posted>
  <last_update_submitted>June 10, 2015</last_update_submitted>
  <last_update_submitted_qc>June 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Constipation</keyword>
  <keyword>C-IBS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

